Shares of Bicycle Therapeutics Limited (NASDAQ:BCYC) have been assigned a consensus recommendation of “Buy” from the six brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $19.00.
A number of research analysts recently issued reports on BCYC shares. Roth Capital started coverage on Bicycle Therapeutics in a research report on Thursday, November 14th. They set a “buy” rating and a $17.00 price objective for the company. Goldman Sachs Group upgraded Bicycle Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 price objective for the company in a research note on Wednesday, September 11th. Canaccord Genuity set a $22.00 target price on Bicycle Therapeutics and gave the stock a “buy” rating in a research report on Monday, September 30th. Finally, Zacks Investment Research upgraded Bicycle Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, December 3rd.
Several institutional investors and hedge funds have recently added to or reduced their stakes in BCYC. Atlas Venture Advisors Inc. acquired a new position in shares of Bicycle Therapeutics during the second quarter worth approximately $13,709,000. Victory Capital Management Inc. bought a new position in Bicycle Therapeutics in the 2nd quarter worth approximately $1,403,000. Pentwater Capital Management LP acquired a new stake in Bicycle Therapeutics in the 2nd quarter valued at approximately $642,000. SV Health Investors LLC acquired a new stake in Bicycle Therapeutics in the 2nd quarter valued at approximately $19,268,000. Finally, Laurion Capital Management LP bought a new stake in Bicycle Therapeutics during the 2nd quarter valued at $1,006,000. 36.27% of the stock is currently owned by institutional investors.
Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Thursday, November 7th. The company reported ($0.53) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.05. The company had revenue of $0.61 million during the quarter, compared to analyst estimates of $1.00 million. Bicycle Therapeutics had a negative return on equity of 238.49% and a negative net margin of 342.94%. Equities research analysts predict that Bicycle Therapeutics will post -3.18 EPS for the current year.
About Bicycle Therapeutics
Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.
Read More: Retained Earnings
Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.